Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 13

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 13
---
 Common Stock issuable upon the exercise of outstanding warrants with a weighted                                              
 average exercise price equal to $2.74 per share;                                                                                       |
| ● | 304,125 shares of Common Stock issuable upon                                                                                           
 the exercise of stock options issued under our equity incentive plans with a weighted average exercise price equal to $6.95 per share; 
 and                                                                                                                                    |
| ● | 1,480,208 shares of our Common Stock that are                                                                                          
 reserved for equity awards that may be granted under our 2024 Equity Incentive Plan.                                                   |

| 5 |

<div align='center'>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Certain statements in this prospectus may contain
“forward-looking statements” within the meaning of the federal securities laws. Our forward-looking statements include, but
are not limited to, statements about us and our industry, as well as statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding the future. Additionally, any statements that refer to projections, forecasts or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. We intend the
forward-looking statements to be covered by the safe harbor provisions of the federal securities laws. Words such as “may,”
“should,” “could,” “would,” “predicts,” “potential,” “continue,”
“expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates,” and similar expressions, as well as statements in future tense, may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking
statements are based on information we have when those statements are made or management’s good faith belief as of that time with
respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ
materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences
include, but are not limited to:

| ● | our projected financial position and estimated cash burn rate;                                                                                                                                                                                                        |
| ● | our estimates regarding expenses, future revenues, and capital requirements;                                                                                                                                                                                          |
| ● | the success, cost, and timing of our clinical trials